Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide is a prescription medicine with a well-studied safety record: clinical trials involving tens of thousands of adults and several years of real-world prescribing show it is safe for most people who meet the licensed criteria, when assessed and monitored by a clinician. It is not suitable for everyone, and side effects are common, particularly in the first few weeks. Because semaglutide is a prescription-only medicine, a prescriber must assess your health before you start, not as a formality but because the safety of treatment genuinely depends on your individual history. Our overview of Wegovy (semaglutide) for weight management explains the treatment in full.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common reason people ask whether semaglutide is safe to take is that they've read about nausea and vomiting and assumed those reactions signal something going wrong. They usually don't. Nausea, loose stools, constipation, indigestion, burping and fatigue are the predictable effects of slowing gastric emptying, and they reflect the medicine working as intended. For most people they peak in the first two to four weeks after starting or after a dose step up, then ease. They're real and can be genuinely uncomfortable, but they're not the same thing as harm.
That said, minimising them isn't useful either. Around three-quarters of participants in the OASIS trial programme reported gastrointestinal effects, compared with roughly four in ten on placebo. The NHS semaglutide medicines page lists these clearly, along with practical advice on managing them. Eating smaller portions, avoiding very fatty or spicy food, and staying hydrated all help. The misconception worth correcting isn't that side effects don't happen; it's that their presence means the treatment is unsafe for you specifically, something our page on whether semaglutide is safe explores in more detail. A prescriber is the right person to make that distinction.
Our clinical team's view, heard regularly during consultations: the people who struggle most are often those who didn't pace their eating changes alongside the dose increases. The medicine asks something of your lifestyle, not just your body.
There are risks with semaglutide that go beyond temporary nausea, and being clear about them is part of what responsible prescribing looks like. Acute pancreatitis is the most important. In January 2026 the MHRA published a Drug Safety Update highlighting acute pancreatitis as a known, infrequent but potentially serious side effect of GLP-1 medicines including semaglutide. The symptom to act on immediately is severe stomach pain that doesn't pass, particularly pain that spreads toward your back, with or without vomiting. That warrants same-day emergency care, not a wait-and-see approach.
Other signals worth knowing: gallbladder problems (gallstones and inflammation have been reported, especially with rapid weight loss), symptoms of dehydration if severe vomiting or diarrhoea prevents you keeping fluids down, and signs of an allergic reaction such as swelling of the face or throat. Sudden changes in vision should also prompt a call to a clinician, particularly for anyone with diabetes-related eye conditions.
These are not common. The trial populations across the STEP programme were large, and rates of serious events remained low. But they're real enough that the MHRA's Yellow Card scheme actively asks patients and clinicians to report any suspected reactions, including ones that might be coincidental. If something feels wrong during treatment, report it. That data shapes how medicines are monitored over time.
Questions about longer-term use come up often too. Our page on how long semaglutide is considered safe to take covers what the evidence currently says.
Semaglutide is not licensed for use in pregnancy, and the MHRA advises using reliable contraception while taking it. Women taking oral contraceptives alongside semaglutide should discuss this with their prescriber; guidance recommends considering additional contraception during and after each dose increase. Anyone who is currently pregnant, breastfeeding or actively trying to conceive should not take semaglutide. Our dedicated page on semaglutide during pregnancy covers the evidence and alternatives in detail.
Other absolute cautions include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a history of pancreatitis, and certain inflammatory gut conditions. People under 18 are not covered by the licence. Those details matter because semaglutide's safety is conditional: safe for most adults with the right clinical profile, and genuinely not appropriate for others.
That's exactly what a clinical consultation is for. At nume, a GPhC-registered prescriber reads every application personally on the same day it's submitted, not a piece of software. They check your medical history, current medicines and relevant background before any decision is made. You can read more about our clinical oversight on the clinical team page. If you have specific questions before starting, our support team is available seven days a week.
Seek urgent medical attention if you develop: severe abdominal pain, especially if it radiates to your back; signs of a serious allergic reaction (facial swelling, difficulty breathing, rash); symptoms of severe dehydration from persistent vomiting or diarrhoea; or unexplained changes in vision.
Contact your prescriber or GP the same day for: injection-site reactions that aren't settling, mood changes or low thoughts that feel linked to treatment, or any symptom that feels outside what you were told to expect.
For milder side effects that aren't resolving, a review of your dose timing or eating habits often helps more than stopping treatment abruptly. It's worth flagging sooner rather than later; our aftercare team is available seven days a week precisely because side-effect questions don't arrive neatly on a weekday morning. Someone starting treatment the week before a bank holiday, or ordering on a Friday payday, deserves the same support as anyone else.
If you'd like a broader picture of what people experience on treatment, our full guide to Wegovy side effects goes through each one in context, and if you want to understand the tolerability profile in more depth, our dedicated page on whether Wegovy is safe to take covers the evidence behind that question. For questions about whether the medicine is right for your situation specifically, the starting point is a free consultation with our prescribers, who discuss suitability and side effects as part of every assessment. You can also explore our weight-loss treatment options if you're still comparing approaches.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.